New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia? | Zendy

Seewoodhary Jason | Zendy; Wong Stephen Phooi Yew | Zendy; Ekanayake Kaharanthilaka Poojanie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?

Author(s) -

Seewoodhary Jason,

Wong Stephen Phooi Yew,

Ekanayake Kaharanthilaka Poojanie

Publication year - 2015

Publication title -

practical diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.205

H-Index - 24

eISSN - 2047-2900

pISSN - 2047-2897

DOI - 10.1002/pdi.1977

Subject(s) - medicine , diabetes mellitus , type 2 diabetes , intensive care medicine , type 1 diabetes , iatrogenic disease , surgery , endocrinology

The barrier of iatrogenic hypoglycaemia has limited the utility and safety of conventional diabetes medications. Novel agents for type 2 diabetes aim to surmount the impediment of iatrogenic hypoglycaemia and unmask the full realisation and benefits of achieving sustained euglycaemia over a lifetime of diabetes. This review aims to critically consider the risk of iatrogenic hypoglycaemia allied with newer agents for type 2 diabetes, used alone and in combination with other diabetes therapies, and how this risk can be minimised. Copyright © 2015 John Wiley & Sons. Copyright © 2015 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research